See veebileht kasutab küpsiseid kasutaja sessiooni andmete hoidmiseks. Veebilehe kasutamisega nõustute ETISe kasutustingimustega. Loe rohkem
Olen nõus
"Muu" projekt SLOMR12214T
SLOMR12214T (3.2.0701.12-0047) "Mitte-invasiivsete biomarkerite arendamine reproduduktiivtervise ja rasedustüsistuste molekaardiagnostikas (1.09.2012−31.08.2015)", Maris Laan, Tartu Ülikool.
3.2.0701.12-0047
SLOMR12214T
Mitte-invasiivsete biomarkerite arendamine reproduduktiivtervise ja rasedustüsistuste molekaardiagnostikas
Development of novel non-invasive biomarkers for fertility and healthy pregnancy
Development of novel non-invasive biomarkers for fertility and healthy pregnancy
1.09.2012
31.08.2015
Teadus- ja arendusprojekt
Muu
ETIS klassifikaatorAlamvaldkondCERCS klassifikaatorFrascati Manual’i klassifikaatorProtsent
3. Terviseuuringud3.1. BiomeditsiinB726 Kliiniline bioloogia 3.1. Biomeditsiin (anatoomia, tsütoloogia, füsioloogia, geneetika, farmaatsia, farmakoloogia, kliiniline keemia, kliiniline mikrobioloogia, patoloogia)100,0
AsutusRollPeriood
Tartu Ülikoolkoordinaator01.09.2012−31.08.2015
AsutusRiikTüüp
SA Archimedes
PerioodSumma
01.09.2012−31.08.2015711 888,30 EUR
711 888,30 EUR
Biotehnoloogia teadus- ja arendustegevuse toetamine

The current proposal in molecular diagnostics represents applied translational research in reproductive biomedicine from the lab to the implementors in clinic and private sector. The main aims include: (1) To test and evaluate the clinical relevance of novel DNA polymorphisms discovered by our research group, and to translate these genetic biomarkers to the routine application in molecular diagnostics in reproductive medicine; to prepare for their potential future assessments in pharmacogenetics. (2) To test and evaluate the clinical prognostic potential of novel maternal blood serum biomarkers in pregnancy complications, identified by our research group; as well as to evaluate the clinical performance of blood serum biomarkers suggested in scientific literature, but not yet applied in Estonian patients; to develop together with the private partner a multi-marker test of these biomarkers for the routine application in clinic. The research groups comprises of basic scientists (reproductive genetics; University of Tartu; Applicant), clinicians (andrology; obstetrics and gynecology; Tartu University Hospital; Partners 1A and 1B) and project implementing partners from public (Department of genetics, United Laboratories, Tartu University Hospital; Partner 1C) and private sectors (Quattromed HTI Laborid OÜ; Partner 2). This project represents a joint effort by a novel academia-clinic-commercial partner consortsium. The project's outcome will lay bases for establishing a strong triangular connection between basic scientists, clinicians and private sector, which is expected (1) to shorten the period from research results to their potential implementer (2) to shorten the period of the transfer of novel outcomes in basic research to clinic (3) to bring together clinic and the commercial developer of the molecular tests for clinical applications (4) to strengthen the link between commercial partner and academia and in need involve academic researchers more actively in assisting to solve research problems (5) to create mutual access to knowledge and infrastructure, including cutting-edge high-throughput, but low-cost/sample Luminex technology by the private partner. In summary, the project paves the way to become a long-term network with a strong potential to further joint projects among the partners in forthcoming years.
The current proposal in molecular diagnostics represents applied translational research in reproductive biomedicine from the lab to the implementors in clinic and private sector. The main aims include: (1) To test and evaluate the clinical relevance of novel DNA polymorphisms discovered by our research group, and to translate these genetic biomarkers to the routine application in molecular diagnostics in reproductive medicine; to prepare for their potential future assessments in pharmacogenetics. (2) To test and evaluate the clinical prognostic potential of novel maternal blood serum biomarkers in pregnancy complications, identified by our research group; as well as to evaluate the clinical performance of blood serum biomarkers suggested in scientific literature, but not yet applied in Estonian patients; to develop together with the private partner a multi-marker test of these biomarkers for the routine application in clinic. The research groups comprises of basic scientists (reproductive genetics; University of Tartu; Applicant), clinicians (andrology; obstetrics and gynecology; Tartu University Hospital; Partners 1A and 1B) and project implementing partners from public (Department of genetics, United Laboratories, Tartu University Hospital; Partner 1C) and private sectors (Quattromed HTI Laborid OÜ; Partner 2). This project represents a joint effort by a novel academia-clinic-commercial partner consortsium. The project's outcome will lay bases for establishing a strong triangular connection between basic scientists, clinicians and private sector, which is expected (1) to shorten the period from research results to their potential implementer (2) to shorten the period of the transfer of novel outcomes in basic research to clinic (3) to bring together clinic and the commercial developer of the molecular tests for clinical applications (4) to strengthen the link between commercial partner and academia and in need involve academic researchers more actively in assisting to solve research problems (5) to create mutual access to knowledge and infrastructure, including cutting-edge high-throughput, but low-cost/sample Luminex technology by the private partner. In summary, the project paves the way to become a long-term network with a strong potential to further joint projects among the partners in forthcoming years.
KirjeldusProtsent
Alusuuring50,0
Rakendusuuring50,0